Baseline characteristics of patients with and without periprocedural cardiac tamponade
| Baseline characteristics . | Tamponade group (n = 200) . | Control group (n = 400) . | P value . |
|---|---|---|---|
| Age (years)a | 63.7 +/− 10.7 | 63.6 +/− 10.6 | 0.989 |
| Male, n (%)a | 106 (53.0) | 212 (53.0) | 1.000 |
| Ischaemic cardiomyopathy | 34 (17.0) | 51 (12.8) | 0.173 |
| Heart failure, n (%) | 28 (14.0) | 46 (11.5) | 0.430 |
| Arterial hypertension, n (%) | 104 (52.0) | 202 (50.5) | 0.795 |
| Diabetes mellitus, n (%) | 20 (10.0) | 25 (6.3) | 0.103 |
| Hyperlipidaemia, n (%) | 40 (20.0) | 77 (19.3) | 0.828 |
| Previous TIA/stroke, n (%) | 21 (10.5) | 25 (6.3) | 0.074 |
| CHA₂DS₂−VASc score ≥2, n (%) | 126 (63.0) | 227 (56.8) | 0.159 |
| Oral anticoagulation/antiplatelet therapy, n (%) | 0.561 | ||
| None | 26 (13.0) | 61 (15.3) | |
| Warfarin | 105 (52.5) | 225 (56.3) | |
| NOAC | 43 (21.5) | 70 (17.5) | |
| ASA or ADP inhibitor | 17 (8.5) | 33 (8.3) | |
| ASA + ADP inhibitor | 2 (1.0) | 1 (0.3) | |
| ASA + warfarin or ASA + NOAC | 7 (3.5) | 10 (2.5) |
| Baseline characteristics . | Tamponade group (n = 200) . | Control group (n = 400) . | P value . |
|---|---|---|---|
| Age (years)a | 63.7 +/− 10.7 | 63.6 +/− 10.6 | 0.989 |
| Male, n (%)a | 106 (53.0) | 212 (53.0) | 1.000 |
| Ischaemic cardiomyopathy | 34 (17.0) | 51 (12.8) | 0.173 |
| Heart failure, n (%) | 28 (14.0) | 46 (11.5) | 0.430 |
| Arterial hypertension, n (%) | 104 (52.0) | 202 (50.5) | 0.795 |
| Diabetes mellitus, n (%) | 20 (10.0) | 25 (6.3) | 0.103 |
| Hyperlipidaemia, n (%) | 40 (20.0) | 77 (19.3) | 0.828 |
| Previous TIA/stroke, n (%) | 21 (10.5) | 25 (6.3) | 0.074 |
| CHA₂DS₂−VASc score ≥2, n (%) | 126 (63.0) | 227 (56.8) | 0.159 |
| Oral anticoagulation/antiplatelet therapy, n (%) | 0.561 | ||
| None | 26 (13.0) | 61 (15.3) | |
| Warfarin | 105 (52.5) | 225 (56.3) | |
| NOAC | 43 (21.5) | 70 (17.5) | |
| ASA or ADP inhibitor | 17 (8.5) | 33 (8.3) | |
| ASA + ADP inhibitor | 2 (1.0) | 1 (0.3) | |
| ASA + warfarin or ASA + NOAC | 7 (3.5) | 10 (2.5) |
Matched variable.
NOAC, novel oral anticoagulant; ASA, acetylsalicylic acid; ADP, adenosine diphosphate receptor.
Baseline characteristics of patients with and without periprocedural cardiac tamponade
| Baseline characteristics . | Tamponade group (n = 200) . | Control group (n = 400) . | P value . |
|---|---|---|---|
| Age (years)a | 63.7 +/− 10.7 | 63.6 +/− 10.6 | 0.989 |
| Male, n (%)a | 106 (53.0) | 212 (53.0) | 1.000 |
| Ischaemic cardiomyopathy | 34 (17.0) | 51 (12.8) | 0.173 |
| Heart failure, n (%) | 28 (14.0) | 46 (11.5) | 0.430 |
| Arterial hypertension, n (%) | 104 (52.0) | 202 (50.5) | 0.795 |
| Diabetes mellitus, n (%) | 20 (10.0) | 25 (6.3) | 0.103 |
| Hyperlipidaemia, n (%) | 40 (20.0) | 77 (19.3) | 0.828 |
| Previous TIA/stroke, n (%) | 21 (10.5) | 25 (6.3) | 0.074 |
| CHA₂DS₂−VASc score ≥2, n (%) | 126 (63.0) | 227 (56.8) | 0.159 |
| Oral anticoagulation/antiplatelet therapy, n (%) | 0.561 | ||
| None | 26 (13.0) | 61 (15.3) | |
| Warfarin | 105 (52.5) | 225 (56.3) | |
| NOAC | 43 (21.5) | 70 (17.5) | |
| ASA or ADP inhibitor | 17 (8.5) | 33 (8.3) | |
| ASA + ADP inhibitor | 2 (1.0) | 1 (0.3) | |
| ASA + warfarin or ASA + NOAC | 7 (3.5) | 10 (2.5) |
| Baseline characteristics . | Tamponade group (n = 200) . | Control group (n = 400) . | P value . |
|---|---|---|---|
| Age (years)a | 63.7 +/− 10.7 | 63.6 +/− 10.6 | 0.989 |
| Male, n (%)a | 106 (53.0) | 212 (53.0) | 1.000 |
| Ischaemic cardiomyopathy | 34 (17.0) | 51 (12.8) | 0.173 |
| Heart failure, n (%) | 28 (14.0) | 46 (11.5) | 0.430 |
| Arterial hypertension, n (%) | 104 (52.0) | 202 (50.5) | 0.795 |
| Diabetes mellitus, n (%) | 20 (10.0) | 25 (6.3) | 0.103 |
| Hyperlipidaemia, n (%) | 40 (20.0) | 77 (19.3) | 0.828 |
| Previous TIA/stroke, n (%) | 21 (10.5) | 25 (6.3) | 0.074 |
| CHA₂DS₂−VASc score ≥2, n (%) | 126 (63.0) | 227 (56.8) | 0.159 |
| Oral anticoagulation/antiplatelet therapy, n (%) | 0.561 | ||
| None | 26 (13.0) | 61 (15.3) | |
| Warfarin | 105 (52.5) | 225 (56.3) | |
| NOAC | 43 (21.5) | 70 (17.5) | |
| ASA or ADP inhibitor | 17 (8.5) | 33 (8.3) | |
| ASA + ADP inhibitor | 2 (1.0) | 1 (0.3) | |
| ASA + warfarin or ASA + NOAC | 7 (3.5) | 10 (2.5) |
Matched variable.
NOAC, novel oral anticoagulant; ASA, acetylsalicylic acid; ADP, adenosine diphosphate receptor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
